TrialAnnals of surgical oncology2026

Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.

Sherko Kuemmel et al.PubMed ↗Publisher ↗

No numbers read from the abstract.